Johnson & Johnson (NYSE:JNJ) Shares Sold by Maltin Wealth Management Inc.

Maltin Wealth Management Inc. lessened its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 27.6% in the 4th quarter, Holdings Channel reports. The firm owned 4,981 shares of the company’s stock after selling 1,901 shares during the period. Maltin Wealth Management Inc.’s holdings in Johnson & Johnson were worth $880,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Glassy Mountain Advisors Inc. purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $35,000. GW&K Investment Management LLC purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $35,000. Dark Forest Capital Management LP grew its stake in Johnson & Johnson by 1,044.4% during the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after acquiring an additional 188 shares in the last quarter. Retirement Financial Solutions LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $40,000. Finally, Kepos Capital LP purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $45,000. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.20% of the company’s stock.

Johnson & Johnson Stock Up 0.1 %

Shares of NYSE JNJ traded up $0.23 during mid-day trading on Friday, reaching $154.64. The company had a trading volume of 3,568,967 shares, compared to its average volume of 7,613,025. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49. The firm has a 50 day simple moving average of $159.89 and a two-hundred day simple moving average of $165.86. The stock has a market cap of $401.87 billion, a P/E ratio of 32.30, a PEG ratio of 2.67 and a beta of 0.53. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $183.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The firm had revenue of $24.75 billion for the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The company’s revenue was up 5.6% on a year-over-year basis. During the same period last year, the firm posted $2.67 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be given a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.08%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 99.58%.

Analyst Ratings Changes

Several analysts have recently weighed in on JNJ shares. Raymond James dropped their price target on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research note on Wednesday, April 19th. Morgan Stanley increased their target price on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 19th. UBS Group assumed coverage on shares of Johnson & Johnson in a report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 target price on the stock. Piper Sandler reduced their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Finally, Credit Suisse Group increased their target price on shares of Johnson & Johnson from $168.00 to $170.00 in a report on Friday, May 5th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $173.00.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.